This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
BioTime (BTX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
BioTime (BTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Achillion (ACHN) Reports Wider-Than-Expected Loss in Q1
by Zacks Equity Research
Achillion (ACHN) reports narrower year-over-year loss in Q1. The absence of an approved product results in no revenues in the quarter.
BioTime (BTX) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
BioTime (BTX) delivered earnings and revenue surprises of 600.00% and 40.61%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Will BioTime (BTX) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
BioTime (BTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioTime (BTX) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
BioTime (BTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Top Ranked Momentum Stocks to Buy for April 2nd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 2nd
Earnings Preview: BioTime (BTX) Q3 Earnings Expected to Decline
by Zacks Equity Research
BioTime (BTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yields on US Treasury Notes Hit Record High: 5 Bank Picks
by Nalak Das
A hike in interest rate will raise the cost of funds, which in turn will enable the financial sector, especially banks
Can The Uptrend Continue for BioTime (BTX)?
by Zacks Equity Research
Investors certainly have to be happy with BioTime, Inc. (BTX) and its short term performance.
BioTime (BTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioTime (BTX) delivered earnings and revenue surprises of 33.33% and 671.82%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
BioTime (BTX) in Focus: Stock Moves 7.3% Higher
by Zacks Equity Research
BioTime (BTX) was a big mover last session, as the company saw its shares rise more than 7% on the day.
BioTime (BTX): Moving Average Crossover Alert
by Zacks Equity Research
BioTime, Inc. (BTX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
BioTime, Inc. (BTX) Looks Good: Stock Adds 6% in Session
by Zacks Equity Research
BioTime (BTX) was a big mover last session, as the company saw its shares rise 6% on the day amid huge volumes.
Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, American Superconductor and Stratasys
by Zacks Equity Research
Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, American Superconductor and Stratasys
Try Rising P/E Investing With 5 Top-Ranked Stocks
by Zacks Equity Research
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, Signal Genetics and Stratasys
by Zacks Equity Research
Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, Signal Genetics and Stratasys
Keep Faith in Rising P/E: Play 5 Top-Ranked Stocks
by Zacks Equity Research
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
Zacks.com featured highlights: Akari Therapeutics, Joint, Tailored Brands, Ardelyx and BioTime
by Zacks Equity Research
Zacks.com featured highlights: Akari Therapeutics, Joint, Tailored Brands, Ardelyx and BioTime
5 Affordable Breakout Stocks Offering Excellent Returns
by Swarup Gupta
If properly implemented, such a strategy has the ability to deliver impressive returns.
Catalyst Pharmaceuticals (CPRX) Posts Loss as Expected in Q1
by Zacks Equity Research
Catalyst Pharmaceuticals, Inc. (CPRX) reported a loss of 6 cents per share in the first quarter of 2017, in line with the Zacks Consensus Estimate but narrower than the loss of 7 cents in the year-ago quarter.
Endocyte (ECYT) Reports Narrower-than-Expected Loss in Q1
by Zacks Equity Research
Endocyte, Inc. (ECYT) reported a narrower-than-expected loss in the first quarter of 2017.
Valeant (VRX) Q1 Earnings & Revenues Miss, View Raised
by Zacks Equity Research
Shares of Valeant Pharmaceuticals Inc. (VRX) surged significantly after the company raised the annual guidance for 2017 concurrent with the first-quarter 2017 earnings.
Prothena (PRTA) Q1 Loss Narrower than Expected, Updates View
by Zacks Equity Research
Prothena Corporation plc (PRTA) reported a loss of 99 cents per share in the first quarter of 2017, wider than the year-ago loss of 81 cents.
Infinity (INFI) Reports Narrower-than-Expected Loss in Q1
by Zacks Equity Research
Infinity Pharmaceuticals, Inc. (INFI) reported a loss of 21 cents per share in first-quarter 2017, narrower than the Zacks Consensus Estimate loss of 22 cents. Also, the company had reported loss of 82 cents in the year-ago quarter.
Endo (ENDP) Beats on Q1 Earnings, Reaffirms '17 Guidance
by Zacks Equity Research
Endo International plc's (ENDP) first-quarter 2017 earnings from continuing operations was $1.23 per share which topped the Zacks Consensus Estimate of $1.12. Earnings were also above the year-ago figure of $1.08.